COVID-19 vaccine: Strides Pharma will produce two hundred million doses of the Russian Sputnik V vaccine

Strides Pharma Science said on Friday that Stelis Biopharma has partnered with Russia’s sovereign wealth fund to produce and source two hundred million doses of the Russian Sputnik V coronavirus vaccine for India. “The agreement between the Russian Direct Investment Fund (RDIF) and Stelis Biopharma was concluded under the umbrella of Enso Healthcare LLP (part of the Enso Group), the coordinating partner of the RDIF for the origin of the Sputnik V vaccines in India,” the pharmacist reported. the manufacturer said in a statement.

Developed by the Russian Gamaleya Institute, Sputnik V is the first registered vaccine against the new coronavirus. It demonstrated a 91. 6% efficacy rate against COVID-19 infection, a peer-reviewed study published in The Lancet showed. Its use has been approved in more than 50 countries, the Russian Direct Investment Fund said.

Commenting on the deal, Arun Kumar, Founder, Strides Group, said: “We are very pleased to partner with RDIF to make a very important contribution to the world of Sputnik V vaccine, which is one of the most effective approved vaccines commercially available. . »

“We will also work with RDIF to increase vaccine availability beyond our initial commitments,” he added.

“The gigantic volumes of vaccines that will be produced jointly with Stelis will help expand the vaccine globally,” said Kirill Dmitriev, managing director of the Russian Direct Investment Fund.

Earlier this week, Gland Pharma Ltd, the Indian unit of China’s Fosun Pharma, signed a deal to produce 252 million doses of the Sputnik V COVID-19 vaccine at its Hyderabad plant.

Last year, Dr. Reddy’s partnered with RDIF to conduct clinical trials of Sputnik V and its distribution rights in India. Based on knowledge of the trial, Dr. Reddy’s initiated the emergency use authorization procedure for Sputnik V with the Comptroller General of Medicines of India. (DCGI), the pharmaceutical company announced in February.

Pharmaceutical manufacturer Hetero has also agreed to produce more than a hundred million doses of the Sputnik V vaccine in India.

Download the Mint app and premium items

Log in to our to save your favorites. It will only be a matter of a moment.

Leave a Comment

Your email address will not be published. Required fields are marked *